Assessment of the initial results of pituitary tumor registry at a tertiary hospital of Iran: 2009–2022

• Published in: Journal of diabetes and metabolic disorders 2024-08, Vol.23 (2), p.2143-2149
• Main Authors: Mohseni, Shahrzad, Mirdamadi, Niloofar, Mossavarali, Shervin, Mohajeri-Tehrani, Mohammad Reza, Pejman Sani, Mahnaz
• Format: Article
• Language: English
• Subjects: Diabetes; Endocrinology; Homeopathy; Materia medica and therapeutics; Medical colleges; Medical records; Medicine; Medicine & Public Health; Metabolic Diseases; Physiological aspects; Research Article; Therapeutics
• ISSN: 2251-6581; 2251-6581
• DOI: 10.1007/s40200-024-01481-9

Objectives The Pituitary Tumor Registry intends to provide a platform for clinical research and basic sciences, with an emphasis on disease outcomes. Methods In this retrospective cohort study, all patient data, including demographics, vital signs, symptoms and signs, medical history, medications, past drug history, paraclinical data, treatment modalities, post-surgery follow-up, treatment responsiveness, and pathology reports, have been gathered from the electronic patient records of the Endocrinology and Metabolism Research Center affiliated with Tehran University of Medical Sciences. Results A total of 200 patients with pituitary adenoma were identified. Acromegaly was the most prevalent adenoma, accounting for 35% ( n  = 70) of cases, followed by clinically nonfunctional pituitary adenoma (CNFPA) at 28.5% ( n  = 57), prolactinoma at 23% ( n  = 46), and Cushing disease at 13.5% ( n  = 27). All of the patients with Cushing disease had surgery, with trans-sphenoidal surgery accounting for 92.59%. Prolactinoma was mostly treated with medication (82.60% of cases). Post-operative complications were reported, including cerebrospinal fluid (CSF) leakage in CNFPA cases (24.13%, n  = 7) and diabetes insipidus (DI) in acromegaly (13.46%, n  = 7). Unfortunately, 5 patients died: two with acromegaly, two with CNFPA and one with Cushing disease. Conclusions This registry permits a comprehensive management, long term follow up and treatment outcomes of patients with pituitary adenomas.